Artículos relacionados
Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience
marzo 18, 2024
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 115. Núm. 2. (Febrero 2024)
Background Dupilumab is a new targeted therapy for severe atopic dermatitis (AD) with limited real-world evidence. Objective Explore our experience with dupilumab for AD in clinical practice at a tertiary care center. Material and method […]
[Translated article] Haptens, Proteins, and Atopic Dermatitis
septiembre 26, 2023
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 114. Núm. 4. (Abril 2023)
Atopic dermatitis is a chronic inflammatory disease that is multifactorial in nature. Allergic contact dermatitis and protein contact dermatitis are allergic conditions that may occur in the context of atopic dermatitis and be the cause […]
[Translated article] Patient-Reported Outcome Measures in Real-World Atopic Dermatitis Studies in Spain: A Systematic Review
diciembre 27, 2022
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 113. Núm. 7. (Julio - Agosto 2022)
Atopic dermatitis (AD) is a chronic inflammatory skin disease with symptoms such as pruritus that can be a major burden for patients. Patient-reported outcomes (PRO) complement clinician-reported outcomes in AD. This systematic review aims to […]